---
title: "iBio files Form 25 to withdraw its common stock from NYSE American"
url: "https://aibio.space/news/ibio-files-form-25-withdraw-common-stock-nyse-american/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2025-03-03"
section: "Listings"
tickers: "NASDAQ:IBIO"
source: "https://www.sec.gov/Archives/edgar/data/1420720/000110465925019785/tm257812d2_25.htm"
summary: "The company says it is withdrawing its listing voluntarily and has complied with the exchange's rules for doing so."
---

By the aibio.space news desk.

Sources

- [iBio, Inc. 25 (2025-03-03)](https://www.sec.gov/Archives/edgar/data/1420720/000110465925019785/tm257812d2_25.htm)

[IBIO](https://aibio.space/companies/ibio/)

2025-03-03

# iBio files Form 25 to withdraw its common stock from NYSE American

Tickers [IBIO](https://aibio.space/companies/ibio/)

The company says it is withdrawing its listing voluntarily and has complied with the exchange's rules for doing so.

## Key facts

- **Company**: iBio, Inc. (NASDAQ: IBIO)

- **News type**: Listings

- **Primary source**: [iBio, Inc. 25 (2025-03-03)](https://www.sec.gov/Archives/edgar/data/1420720/000110465925019785/tm257812d2_25.htm)

*Rows of law reports on a shelf. CC0, via rawpixel. The picture shows the field, not the companies named.*

iBio, Inc. filed a Form 25 on March 3, 2025 to withdraw its common stock, par value $0.001 per share, from listing and registration on NYSE American LLC.

A Form 25 is the SEC notice that removes a class of securities from listing on a national exchange. iBio checked the box for 17 CFR 240.12d2-2(c), the rule that covers a voluntary withdrawal by the issuer. By doing so, the company certified that it "has complied with the rules of the Exchange" and the SEC requirements that govern a voluntary exit.

The [notice](https://www.sec.gov/Archives/edgar/data/1420720/000110465925019785/tm257812d2_25.htm) lists the company, a Delaware corporation, at 11750 Sorrento Valley Road in San Diego, California, and gives Commission File Number 001-35023. A filing note says the Form 25 and attached notice count toward compliance with 17 CFR 240.19d-1 as applicable.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

IBIO

iBio, Inc.

NASDAQ · United States

Open the starter desk

## More in Listings

Listings

### [Propanc Biopharma faces Nasdaq delisting on bid price, plans to appeal](https://aibio.space/news/propanc-biopharma-faces-nasdaq-delisting-bid-price-plans-appeal/)

Oct 29, 2026

Listings

### [Reviva asks stockholders to approve reverse split of up to 1-for-100](https://aibio.space/news/reviva-asks-stockholders-approve-reverse-split-up-1-100/)

Oct 29, 2026

Listings

### [Nasdaq to delist Glucotrack shares after bid price exception ends](https://aibio.space/news/nasdaq-delist-glucotrack-shares-after-bid-price-exception-ends/)

Oct 28, 2026

---
Source page: https://aibio.space/news/ibio-files-form-25-withdraw-common-stock-nyse-american/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "iBio files Form 25 to withdraw its common stock from NYSE American", 2025-03-03, https://aibio.space/news/ibio-files-form-25-withdraw-common-stock-nyse-american/